Amicus Therapeutics, Inc. Share Price FOLD

$14.49

▲

0.03

(0.21%)

Last updated on April 24, 2026 at 12:00 am IST

$₹

This instrument is not available for trading on the INDmoney app on 24 Apr 2026

Check the interactive Amicus Therapeutics, Inc. Stock chart to analyse performance

Amicus Therapeutics, Inc. Key Stats

Check Amicus Therapeutics, Inc. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$14.46
Open	$14.49
Market Capitalization	$4.5B
Today's Volume	$5.3M
Revenue TTM	$634.2M
EBITDA	$42.0M
Earnings Per Share (EPS)	$-0.09
Profit Margin	-4.28%
Quarterly Earnings Growth YOY	-0.95%
Return On Equity TTM	-11.58%

Global Institutional Holdings in Amicus Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
9.46%
Wellington Management Company LLP
9.45%
BlackRock Inc
8.23%
venBio Select Advisor LLC
4.79%
Millennium Management LLC
3.76%
State Street Corp
3.68%

Analyst Recommendation on Amicus Therapeutics, Inc. Stock

Rating

Trend

Buy

76%Buy

23%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for Amicus Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

Amicus Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY16

FY17

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

	FY16	Y/Y Change
Revenue	$5.0M	-
Net Income	$-200.0M	-
Net Profit Margin	-4.0K%	-

	FY17	Y/Y Change
Revenue	$36.9M	↑ 644.86%
Net Income	$-284.0M	↑ 41.97%
Net Profit Margin	-769.03%	↑ 3265.7%

	FY18	Y/Y Change
Revenue	$91.2M	↑ 147.08%
Net Income	$-349.0M	↑ 22.88%
Net Profit Margin	-382.48%	↑ 386.55%

	FY19	Y/Y Change
Revenue	$182.2M	↑ 99.72%
Net Income	$-356.4M	↑ 2.12%
Net Profit Margin	-195.56%	↑ 186.92%

	FY20	Y/Y Change
Revenue	$260.9M	↑ 43.16%
Net Income	$-276.9M	↓ 22.32%
Net Profit Margin	-106.12%	↑ 89.44%

	FY21	Y/Y Change
Revenue	$305.5M	↑ 17.11%
Net Income	$-250.5M	↓ 9.53%
Net Profit Margin	-81.98%	↑ 24.14%

	FY22	Y/Y Change
Revenue	$329.2M	↑ 7.76%
Net Income	$-236.6M	↓ 5.55%
Net Profit Margin	-71.85%	↑ 10.13%

	FY23	Y/Y Change
Revenue	$399.4M	↑ 21.3%
Net Income	$-151.6M	↓ 35.92%
Net Profit Margin	-37.96%	↑ 33.89%

	FY24	Y/Y Change
Revenue	$528.3M	↑ 32.29%
Net Income	$-56.1M	↓ 62.99%
Net Profit Margin	-10.62%	↑ 27.34%

	FY25	Y/Y Change
Revenue	$634.2M	↑ 20.05%
Net Income	$-27.1M	↓ 51.68%
Net Profit Margin	-4.27%	↑ 6.35%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY23	Q/Q Change
Revenue	$103.5M	-
Net Income	$-21.6M	-
Net Profit Margin	-20.85%	-

	Q4 FY23	Q/Q Change
Revenue	$115.1M	↑ 11.19%
Net Income	$-33.8M	↑ 56.85%
Net Profit Margin	-29.41%	↓ 8.56%

	Q1 FY24	Q/Q Change
Revenue	$110.4M	↓ 4.07%
Net Income	$-48.4M	↑ 43.07%
Net Profit Margin	-43.86%	↓ 14.45%

	Q2 FY24	Q/Q Change
Revenue	$126.7M	↑ 14.73%
Net Income	$-15.7M	↓ 67.58%
Net Profit Margin	-12.39%	↑ 31.47%

	Q3 FY24	Q/Q Change
Revenue	$141.5M	↑ 11.72%
Net Income	$-6.7M	↓ 57.13%
Net Profit Margin	-4.75%	↑ 7.64%

	Q4 FY24	Q/Q Change
Revenue	$149.7M	↑ 5.79%
Net Income	$14.7M	↓ 319.04%
Net Profit Margin	9.85%	↑ 14.6%

	Q1 FY25	Q/Q Change
Revenue	$125.2M	↓ 16.34%
Net Income	$-21.7M	↓ 247.13%
Net Profit Margin	-17.31%	↓ 27.16%

	Q2 FY25	Q/Q Change
Revenue	$154.7M	↑ 23.5%
Net Income	$-24.4M	↑ 12.61%
Net Profit Margin	-15.79%	↑ 1.52%

	Q3 FY25	Q/Q Change
Revenue	$169.1M	↑ 9.29%
Net Income	$17.3M	↓ 170.87%
Net Profit Margin	10.24%	↑ 26.03%

	Q4 FY25	Q/Q Change
Revenue	$185.2M	↑ 9.55%
Net Income	$1.7M	↓ 90.23%
Net Profit Margin	0.91%	↓ 9.33%

FY16

FY17

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

	FY16	Y/Y Change
Profit	$4.1M	-

	FY17	Y/Y Change
Profit	$30.7M	↑ 644.1%

	FY18	Y/Y Change
Profit	$76.8M	↑ 150.35%

	FY19	Y/Y Change
Profit	$160.3M	↑ 108.58%

	FY20	Y/Y Change
Profit	$229.8M	↑ 43.41%

	FY21	Y/Y Change
Profit	$271.0M	↑ 17.93%

	FY22	Y/Y Change
Profit	$290.6M	↑ 7.23%

	FY23	Y/Y Change
Profit	$362.0M	↑ 24.57%

	FY24	Y/Y Change
Profit	$475.4M	↑ 31.3%

	FY25	Y/Y Change
Profit	$553.8M	↑ 16.51%

Q3 FY23

Q4 FY23

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY23	Q/Q Change
Profit	$93.6M	-

	Q4 FY23	Q/Q Change
Profit	$103.8M	↑ 10.91%

	Q1 FY24	Q/Q Change
Profit	$96.8M	↓ 6.67%

	Q2 FY24	Q/Q Change
Profit	$115.4M	↑ 19.18%

	Q3 FY24	Q/Q Change
Profit	$128.2M	↑ 11.12%

	Q4 FY24	Q/Q Change
Profit	$134.9M	↑ 5.17%

	Q1 FY25	Q/Q Change
Profit	$113.6M	↓ 15.81%

	Q2 FY25	Q/Q Change
Profit	$139.5M	↑ 22.83%

	Q3 FY25	Q/Q Change
Profit	$147.7M	↑ 5.91%

	Q4 FY25	Q/Q Change
Profit	$156.8M	↑ 6.13%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$-233.3M	↓ 6.84%
Investing Cash Flow	$-13.6M	↓ 114.27%
Financing Cash Flow	$262.9M	↑ 20.85%

	FY21	Y/Y Change
Operating Cash Flow	$-202.5M	↓ 13.2%
Investing Cash Flow	$78.8M	↓ 680.02%
Financing Cash Flow	$212.1M	↓ 19.32%

	FY22	Y/Y Change
Operating Cash Flow	$-166.6M	↓ 17.74%
Investing Cash Flow	$92.3M	↑ 17.21%
Financing Cash Flow	$-7.5M	↓ 103.52%

	FY23	Y/Y Change
Operating Cash Flow	$-69.1M	↓ 58.52%
Investing Cash Flow	$98.1M	↑ 6.23%
Financing Cash Flow	$61.7M	↓ 926.44%

	FY24	Y/Y Change
Operating Cash Flow	$-33.9M	↓ 50.95%
Investing Cash Flow	$-560.0K	↓ 100.57%
Financing Cash Flow	$5.1M	↓ 91.7%

	FY25	Y/Y Change
Operating Cash Flow	$33.1M	↓ 197.8%
Investing Cash Flow	$-46.4M	↑ 8191.43%
Financing Cash Flow	$610.0K	↓ 88.09%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-23.0M	↓ 201.23%
Investing Cash Flow	$34.3M	↓ 255.94%
Financing Cash Flow	$18.2M	↓ 2222.52%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-3.9M	↓ 82.95%
Investing Cash Flow	$-20.4M	↓ 159.5%
Financing Cash Flow	$1.1M	↓ 93.97%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$7.8M	↓ 298.11%
Investing Cash Flow	$-32.9M	↑ 61.15%
Financing Cash Flow	$-11.7M	↓ 1166.55%

	Q4 FY25	Q/Q Change
Operating Cash Flow	$16.3M	↓ 54.42%
Investing Cash Flow	$-6.5M	↑ 399.92%
Financing Cash Flow	$14.0M	↓ 1163.61%

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Organization	Amicus Therapeutics, Inc.
Employees	511
CEO	Mr. Bradley L. Campbell M.B.A.
Industry	Healthcare

Key Management of Amicus Therapeutics, Inc.

Name	Title
Mr. Bradley L. Campbell M.B.A.	CEO, President & Director
Mr. Simon Nicolas Reade Harford	Chief Financial Officer
Ms. Ellen S. Rosenberg J.D.	Chief Legal Officer & Corporate Secretary
Mr. David M. Clark	Chief People Officer
Dr. Jeffrey P. Castelli Ph.D.	Chief Development Officer
Ms. Samantha L. Prout	Chief Accounting Officer & Controller
Dr. Jill Weimer Ph.D.	Chief Science Officer
Mr. Andrew Faughnan	Vice President of Investor Relations
Mr. Patrik S. Florencio Esq.	Global Chief Compliance & Risk Officer
Mr. Brendan McEvoy	Executive Director of External Communications

Important FAQs about investing in FOLD Stock from India :

What is Amicus Therapeutics, Inc. share price today?

Amicus Therapeutics, Inc. share price today is $14.49 as on April 24, 2026 at 12:00 am IST at the close of the market. Amicus Therapeutics, Inc. share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Amicus Therapeutics, Inc. share?

Amicus Therapeutics, Inc. share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Amicus Therapeutics, Inc. stock price today i.e. April 24, 2026 at 12:00 am IST is closed at $14.49, lower by 0.07% versus the 52 week high.

How to invest in Amicus Therapeutics, Inc. Stock (FOLD) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Amicus Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Amicus Therapeutics, Inc. Shares that will get you 0.1035 shares as per Amicus Therapeutics, Inc. share price of $14.49 per share as on April 24, 2026 at 12:00 am IST.

What is the minimum amount required to buy Amicus Therapeutics, Inc. Stock (FOLD) from India?

Indian investors can start investing in Amicus Therapeutics, Inc. (FOLD) shares with as little as ₹95.3725 or $1 (as of July 07, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹953.73 in Amicus Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on July 07, 2026). Based on Amicus Therapeutics, Inc. share’s latest price of $14.49 as on April 24, 2026 at 12:00 am IST, you will get 0.6901 shares of Amicus Therapeutics, Inc.. Learn more about fractional shares .

What are the returns that Amicus Therapeutics, Inc. has given to Indian investors in the last 5 years?

Amicus Therapeutics, Inc. stock has given 0.0% share price returns and 28.33% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Chain Bridge I
$4.33
-12.17%
Functional Brands, Inc. Common Stock
$0.00
+0.0%
Sleep Number Corporation Common Stock
$0.12
-42.86%
Aditxt, Inc. Common Stock
$0.00
-100.0%
Middleby Corp. Common Stock Ex-Distribution When Issued
$142.45
+2.1%
Two Roads Shared Trust Liberty One Spectrum ETF
$27.57
-0.04%
Abeona Therapeutics Inc. Common Stock
$6.31
-1.41%
BHAV Acquisition Corp Units
$10.10
+0.0%
JPMorgan BetaBuilders U.S. Equity ETF
$135.44
+0.83%

Explore all

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-26.5M	↓ 441.92%
Investing Cash Flow	$-5.8M	↓ 82.42%
Financing Cash Flow	$-400.0K	↓ 96.58%

	Q3 FY25	Q/Q Change
Operating Cash Flow	$35.7M	↓ 234.43%
Investing Cash Flow	$-1.3M	↓ 77.52%
Financing Cash Flow	$-1.3M	↑ 229.75%